Published in J Biol Chem on April 06, 2008
The mononuclear molybdenum enzymes. Chem Rev (2014) 1.55
The impact of single nucleotide polymorphisms on human aldehyde oxidase. Drug Metab Dispos (2012) 1.12
Overexpression, isolation, and spectroscopic characterization of the bidirectional [NiFe] hydrogenase from Synechocystis sp. PCC 6803. J Biol Chem (2009) 0.99
The CoxD protein of Oligotropha carboxidovorans is a predicted AAA+ ATPase chaperone involved in the biogenesis of the CO dehydrogenase [CuSMoO2] cluster. J Biol Chem (2009) 0.97
The first mammalian aldehyde oxidase crystal structure: insights into substrate specificity. J Biol Chem (2012) 0.96
Site directed mutagenesis of amino acid residues at the active site of mouse aldehyde oxidase AOX1. PLoS One (2009) 0.94
Molecular analysis of an extrachromosomal element containing the C2 toxin gene discovered in Clostridium botulinum type C. J Bacteriol (2009) 0.91
A Rhodobacter capsulatus member of a universal permease family imports molybdate and other oxyanions. J Bacteriol (2010) 0.89
The role of system-specific molecular chaperones in the maturation of molybdoenzymes in bacteria. Biochem Res Int (2010) 0.89
The aerobic CO dehydrogenase from Oligotropha carboxidovorans. J Biol Inorg Chem (2014) 0.81
Xanthine dehydrogenase: An old enzyme with new knowledge and prospects. Bioengineered (2016) 0.79
The role of FeS clusters for molybdenum cofactor biosynthesis and molybdoenzymes in bacteria. Biochim Biophys Acta (2014) 0.76
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Definition and classification of cancer cachexia: an international consensus. Lancet Oncol (2011) 7.78
Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60
The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation (2006) 6.58
Frailty consensus: a call to action. J Am Med Dir Assoc (2013) 6.54
Cachexia: a new definition. Clin Nutr (2008) 5.49
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89
Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet (2008) 3.71
Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J (2009) 3.52
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35
State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. Circulation (2009) 3.05
The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J (2005) 2.92
Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation (2011) 2.87
Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation (2002) 2.71
Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr (2006) 2.67
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail (2010) 2.64
Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J (2012) 2.60
The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc (2010) 2.55
A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J (2010) 2.52
Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle (2010) 2.49
Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol (2007) 2.46
Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc (2011) 2.34
Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol (2005) 2.28
Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol (2010) 2.25
Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation (2007) 2.22
Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol (2009) 2.20
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J (2011) 2.14
The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol (2003) 2.12
Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol (2012) 2.11
Mutational analysis of Deinococcus radiodurans bacteriophytochrome reveals key amino acids necessary for the photochromicity and proton exchange cycle of phytochromes. J Biol Chem (2008) 2.06
Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle (2010) 2.04
Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation (2006) 2.00
Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J (2013) 1.99
Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol (2005) 1.99
Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol (2007) 1.92
An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle (2010) 1.89
Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol (2011) 1.89
Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.86
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J (2008) 1.84
Anemia and inflammation in COPD. Chest (2005) 1.83
Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care (2007) 1.82
Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. Eur Heart J (2007) 1.75
Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail (2009) 1.73
Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation (2002) 1.70
Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J Cachexia Sarcopenia Muscle (2014) 1.68
Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail (2011) 1.61
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.61
Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ Res (2007) 1.61
Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol (2011) 1.59
Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation (2004) 1.59
Anorexia in chronic obstructive pulmonary disease--association to cachexia and hormonal derangement. Int J Cardiol (2006) 1.58
Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation (2002) 1.58
Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol (2008) 1.57
Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. Eur J Heart Fail (2012) 1.56
Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: a propensity-matched study. Eur J Heart Fail (2010) 1.55
Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail (2003) 1.54
Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail (2013) 1.53
Highly conserved residues Asp-197 and His-250 in Agp1 phytochrome control the proton affinity of the chromophore and Pfr formation. J Biol Chem (2006) 1.52
Nutritional recommendations for the management of sarcopenia. J Am Med Dir Assoc (2010) 1.51
Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014. J Cachexia Sarcopenia Muscle (2014) 1.50
Light-induced proton release of phytochrome is coupled to the transient deprotonation of the tetrapyrrole chromophore. J Biol Chem (2005) 1.50
A unique iron-sulfur cluster is crucial for oxygen tolerance of a [NiFe]-hydrogenase. Nat Chem Biol (2011) 1.50
Cardiac cachexia: a systematic overview. Pharmacol Ther (2008) 1.49
Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol (2007) 1.48
C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J (2009) 1.48
The small intestine: a critical linkage in pathophysiology of cardiac cachexia. Int J Cardiol (2010) 1.46
The sulfurtransferase activity of Uba4 presents a link between ubiquitin-like protein conjugation and activation of sulfur carrier proteins. Biochemistry (2008) 1.44
Self-rated health predicts adverse events during β-blocker treatment: the CIBIS-ELD randomised trial analysis. Int J Cardiol (2011) 1.44
The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle. J Am Coll Cardiol (2005) 1.43
Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure - Subanalysis of the WARCEF Trial. Circ J (2016) 1.43
Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle (2013) 1.42
Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J (2010) 1.42
A novel role for human Nfs1 in the cytoplasm: Nfs1 acts as a sulfur donor for MOCS3, a protein involved in molybdenum cofactor biosynthesis. J Biol Chem (2008) 1.41
The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study. Eur J Heart Fail (2013) 1.41
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2011) 1.40
Vitamin D in chronic kidney disease: more questions than answers. JAMA (2012) 1.39
Predictors of clinical outcomes in elderly patients with heart failure. Eur J Heart Fail (2011) 1.39
Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: a randomized double-blinded placebo-controlled study. Int J Cardiol (2012) 1.39
PRESTO (a mammoth trial that could have been prevented), HPS and REMATCH. Int J Cardiol (2002) 1.38
Displacement of the tyrosyl radical cofactor in ribonucleotide reductase obtained by single-crystal high-field EPR and 1.4-A x-ray data. Proc Natl Acad Sci U S A (2003) 1.38
Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. Int J Cardiol (2009) 1.38
Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia. J Cachexia Sarcopenia Muscle (2012) 1.37
The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle (2011) 1.36
Crystal structures of the active and alloxanthine-inhibited forms of xanthine dehydrogenase from Rhodobacter capsulatus. Structure (2002) 1.35
The obesity paradox in chronic disease: facts and numbers. J Cachexia Sarcopenia Muscle (2012) 1.35
The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J (2005) 1.34
Pathophysiology of peripheral muscle wasting in cardiac cachexia. Curr Opin Clin Nutr Metab Care (2005) 1.27
Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest (2005) 1.27
Trapping and characterization of a reaction intermediate in carbapenem hydrolysis by B. cereus metallo-beta-lactamase. J Am Chem Soc (2008) 1.26
Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J (2011) 1.26
The chromophore structural changes during the photocycle of phytochrome: a combined resonance Raman and quantum chemical approach. Acc Chem Res (2007) 1.25
Determination of the chromophore structures in the photoinduced reaction cycle of phytochrome. J Am Chem Soc (2004) 1.24